A major goal of the neuroscience community is to develop treatment strategies that will slow or forestall the progression of chronic neurodegenerative diseases. Parkinson's disease (PD) is one of the most common adult neurodegenerative disorders, affecting over 1 million people in North America and the European Union, As a first step in identifying such therapies, the NINDS Exploratory Trials in Parkinson's disease (NET-PD) network successfully completed futility studies, which identified creatine as a potential agent to slow clinical decline in PD. The NET-PD network is now conducting a large, long-term, Phase 3 trial (known as LSI) comparing creatine to placebo. An additional futility study is underway (the FS-ZONE study) to examine the potential for pioglitazone as a disease modifying therapy in PD.

Public Health Relevance

The accumulated disability that PD causes is a major source of diminished quality of life and increased health care costs. Despite the advances in our understanding of the pathophysiology in PD, there are no current therapies that slow the inexorable clinical decline. LSI will help to determine if creatine can slow clinical decline and provide better information on the course of early PD than is currently available.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1-SRB-B (34))
Program Officer
Moy, Claudia S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Simon, David K; Wu, Cai; Tilley, Barbara C et al. (2017) Caffeine, creatine, GRIN2A and Parkinson's disease progression. J Neurol Sci 375:355-359
Wills, Anne-Marie A; Elm, Jordan J; Ye, Rong et al. (2016) Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism Relat Disord 33:127-133
Wills, Anne-Marie A; PĂ©rez, Adriana; Wang, Jue et al. (2016) Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1 JAMA Neurol 73:321-8
Simon, David K; Simuni, Tanya; Elm, Jordan et al. (2015) Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. J Parkinsons Dis 5:731-6
Simon, David K; Wu, Cai; Tilley, Barbara C et al. (2015) Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol 38:163-9
Elm, Jordan J; NINDS NET-PD Investigators (2012) Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord 27:1513-21
Pankratz, Nathan; Beecham, Gary W; DeStefano, Anita L et al. (2012) Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol 71:370-84
Xiao, J; Zhao, Y; Bastian, R W et al. (2010) Novel THAP1 sequence variants in primary dystonia. Neurology 74:229-38